Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant.

Deng Q, Hu H, Yu X, Liu S, Wang L, Chen W, Zhang C, Zeng Z, Cao Y, Xu-Monette ZY, Li L, Zhang M, Rosenfeld S, Bao S, Hsi E, Young KH, Lu Z, Li Y.

Nat Commun. 2019 Nov 7;10(1):5061. doi: 10.1038/s41467-019-13002-x.

2.

Hematopoietic stem cell transplantation for adults with T-cell lymphoblastic lymphoma: can we successfully step into the era of precision medicine?

Young KH.

Leukemia. 2019 Oct 22. doi: 10.1038/s41375-019-0608-4. [Epub ahead of print] No abstract available.

PMID:
31641192
3.

Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.

Xu-Monette ZY, Li J, Xia Y, Crossley B, Bremel RD, Miao Y, Xiao M, Snyder T, Manyam GC, Tan X, Zhang H, Visco C, Tzankov A, Dybkaer K, Bhagat G, Tam W, You H, Hsi ED, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Winter JN, Medeiros JT, Xu B, Li Y, Kirsch I, Young KH.

J Immunother Cancer. 2019 Oct 22;7(1):272. doi: 10.1186/s40425-019-0730-x.

4.

Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract.

Soderquist CR, Patel N, Murty VV, Betman S, Aggarwal N, Young KH, Xerri L, Leeman-Neill R, Lewis SK, Green PH, Hsiao S, Mansukhani MM, Hsi ED, de Leval L, Alobeid B, Bhagat G.

Haematologica. 2019 Sep 26. pii: haematol.2019.230961. doi: 10.3324/haematol.2019.230961. [Epub ahead of print]

5.

Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma.

Li Z, Zhang X, Xue W, Zhang Y, Li C, Song Y, Mei M, Lu L, Wang Y, Zhou Z, Jin M, Bian Y, Zhang L, Wang X, Li L, Li X, Fu X, Sun Z, Wu J, Nan F, Chang Y, Yan J, Yu H, Feng X, Wang G, Zhang D, Fu X, Zhang Y, Young KH, Li W, Zhang M.

Nat Commun. 2019 Sep 16;10(1):4209. doi: 10.1038/s41467-019-12032-9.

6.

B-cell acute lymphoblastic leukemia/lymphoma in relapse presenting as a cervical mass: A case report and review of literature.

Kazma J, Johnson C, Jain N, Gali VL, Young KH, Jazaeri AA.

Gynecol Oncol Rep. 2019 Aug 12;29:94-97. doi: 10.1016/j.gore.2019.08.003. eCollection 2019 Aug.

7.

Genomic and outcome analysis of adult T-cell lymphoblastic lymphoma.

Li Z, Song Y, Zhang Y, Li C, Wang Y, Xue W, Lu L, Jin M, Zhou Z, Wang X, Li L, Zhang L, Li X, Fu X, Sun Z, Wu J, Zhang X, Yu H, Nan F, Chang Y, Yan J, Feng X, Wu X, Wang G, Zhang D, Li W, Li F, Zhang Y, Young KH, Zhang M.

Haematologica. 2019 Aug 14. pii: haematol.2019.220863. doi: 10.3324/haematol.2019.220863. [Epub ahead of print]

8.

A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma.

Lyapichev KA, Piña-Oviedo S, Medeiros LJ, Evans MG, Liu H, Miranda AR, Hunt KK, Clemens MW, Stewart JM, Amin MB, Quesada AE, Chai SM, Di Napoli A, Yoga A, Dave SK, Wistuba II, Wu Y, Bueso-Ramos CE, Schlette EJ, Ferrufino-Schmidt MC, Loghavi S, Khoury JD, Young KH, Miranda RN.

Mod Pathol. 2019 Aug 5. doi: 10.1038/s41379-019-0337-2. [Epub ahead of print]

PMID:
31383966
9.

Glyphosate induces benign monoclonal gammopathy and promotes multiple myeloma progression in mice.

Wang L, Deng Q, Hu H, Liu M, Gong Z, Zhang S, Xu-Monette ZY, Lu Z, Young KH, Ma X, Li Y.

J Hematol Oncol. 2019 Jul 5;12(1):70. doi: 10.1186/s13045-019-0767-9.

10.

Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases.

Kim DH, Medeiros LJ, Aung PP, Young KH, Miranda RN, Ok CY.

Am J Surg Pathol. 2019 Oct;43(10):1421-1428. doi: 10.1097/PAS.0000000000001312.

PMID:
31219818
11.

Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.

Liu H, He J, Koh SP, Zhong Y, Liu Z, Wang Z, Zhang Y, Li Z, Tam BT, Lin P, Xiao M, Young KH, Amini B, Starbuck MW, Lee HC, Navone NM, Davis RE, Tong Q, Bergsagel PL, Hou J, Yi Q, Orlowski RZ, Gagel RF, Yang J.

Sci Transl Med. 2019 May 29;11(494). pii: eaau9087. doi: 10.1126/scitranslmed.aau9087.

PMID:
31142679
12.

Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma.

Cai Q, Cai J, Fang Y, Young KH.

Front Oncol. 2019 May 14;9:386. doi: 10.3389/fonc.2019.00386. eCollection 2019. Review.

13.

Genetic alterations and their clinical implications in DLBCL.

Miao Y, Medeiros LJ, Li Y, Li J, Young KH.

Nat Rev Clin Oncol. 2019 Oct;16(10):634-652. doi: 10.1038/s41571-019-0225-1. Review.

PMID:
31127191
14.

Current perspectives on the treatment of double hit lymphoma.

Li LR, Wang L, He YZ, Young KH.

Expert Rev Hematol. 2019 Jul;12(7):507-514. doi: 10.1080/17474086.2019.1623020. Epub 2019 May 27.

PMID:
31117849
15.

Uncovering the role of hnRNP K, an RNA-binding protein, in B-cell lymphomas.

Gallardo M, Malaney P, Aitken MJL, Zhang X, Link TM, Shah V, Alybayev S, Wu MH, Pageon LR, Ma H, Jacamo R, Yu L, Xu-Monette ZY, Steinman H, Lee HJ, Sarbassov D, Rapado I, Barton MC, Martinez-Lopez J, Bueso-Ramos C, Young KH, Post SM.

J Natl Cancer Inst. 2019 May 11. pii: djz078. doi: 10.1093/jnci/djz078. [Epub ahead of print]

PMID:
31077320
16.

Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses.

Cascione L, Rinaldi A, Bruscaggin A, Tarantelli C, Arribas AJ, Kwee I, Pecciarini L, Mensah AA, Spina V, Chung EYL, di Bergamo LT, Dirnhofer S, Tzankov A, Miranda RN, Young KH, Traverse-Glehen A, Gaidano G, Swerdlow SH, Gascoyne R, Rabadan R, Ponzoni M, Bhagat G, Rossi D, Zucca E, Bertoni F.

Haematologica. 2019 Dec;104(12):e558-e561. doi: 10.3324/haematol.2018.214957. Epub 2019 Apr 24. No abstract available.

17.

MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma.

Due H, Schönherz AA, Ryø L, Primo MN, Jespersen DS, Thomsen EA, Roug AS, Xiao M, Tan X, Pang Y, Young KH, Bøgsted M, Mikkelsen JG, Dybkær K.

Blood Adv. 2019 Apr 9;3(7):1185-1196. doi: 10.1182/bloodadvances.2018029660.

18.

Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.

Miao Y, Medeiros LJ, Xu-Monette ZY, Li J, Young KH.

Front Oncol. 2019 Mar 1;9:107. doi: 10.3389/fonc.2019.00107. eCollection 2019. Review.

19.

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.

Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1347-1354. doi: 10.1016/j.bbmt.2019.02.022. Epub 2019 Mar 1.

PMID:
30826465
20.

Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.

Xu-Monette ZY, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodríguez-Perales S, Torres-Ruiz R, Manyam GC, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkær K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH.

Cancer Immunol Res. 2019 Apr;7(4):644-657. doi: 10.1158/2326-6066.CIR-18-0439. Epub 2019 Feb 11.

PMID:
30745366
21.

Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.

Gunderson AJ, Yamazaki T, McCarty K, Phillips M, Alice A, Bambina S, Zebertavage L, Friedman D, Cottam B, Newell P, Gough MJ, Crittenden MR, Van der Veken P, Young KH.

PLoS One. 2019 Feb 6;14(2):e0211117. doi: 10.1371/journal.pone.0211117. eCollection 2019.

22.

PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.

Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, Xu B, Manyam GC, Tan X, Zhang H, Xiao M, Tzankov A, Visco C, Dybkaer K, Bhagat G, Tam W, Hsi ED, van Krieken JH, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Zhang M, Winter JN, Medeiros LJ, Rassidakis GZ, Vaupel CA, Li Y, Dakappagari N, Xu-Monette ZY, Young KH.

Mod Pathol. 2019 Jun;32(6):741-754. doi: 10.1038/s41379-018-0193-5. Epub 2019 Jan 21.

PMID:
30666052
23.

Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment.

Cai Q, Fang Y, Young KH.

Transl Oncol. 2019 Mar;12(3):523-538. doi: 10.1016/j.tranon.2018.11.011. Epub 2019 Jan 4. Review.

24.

Recurrent PDGFRB mutations in unicentric Castleman disease.

Li Z, Lan X, Li C, Zhang Y, Wang Y, Xue W, Lu L, Jin M, Zhou Z, Wang X, Li L, Zhang L, Li X, Fu X, Sun Z, Wu J, Zhang X, Yu H, Nan F, Chang Y, Yan J, Wu X, Wang G, Zhang D, Zhang Y, Young KH, Zhang M.

Leukemia. 2019 Apr;33(4):1035-1038. doi: 10.1038/s41375-018-0323-6. Epub 2019 Jan 3. No abstract available.

25.

Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.

Peng RJ, Han BW, Cai QQ, Zuo XY, Xia T, Chen JR, Feng LN, Lim JQ, Chen SW, Zeng MS, Guo YM, Li B, Xia XJ, Xia Y, Laurensia Y, Chia BKH, Huang HQ, Young KH, Lim ST, Ong CK, Zeng YX, Bei JX.

Leukemia. 2019 Jun;33(6):1451-1462. doi: 10.1038/s41375-018-0324-5. Epub 2018 Dec 13.

26.

Exploring optimal sequencing of radiation and immunotherapy combinations.

Gunderson AJ, Young KH.

Adv Radiat Oncol. 2018 Oct 23;3(4):494-505. doi: 10.1016/j.adro.2018.07.005. eCollection 2018 Oct-Dec. Review.

27.

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces peripheral blood abnormalities and plasma cell neoplasms resembling multiple myeloma in mice.

Wang L, Kumar M, Deng Q, Wang X, Liu M, Gong Z, Zhang S, Ma X, Xu-Monette ZY, Xiao M, Yi Q, Young KH, Ramos KS, Li Y.

Cancer Lett. 2019 Jan;440-441:135-144. doi: 10.1016/j.canlet.2018.10.009. Epub 2018 Oct 19.

PMID:
30343114
28.

Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.

Zhang J, Medeiros LJ, Young KH.

Front Oncol. 2018 Sep 10;8:351. doi: 10.3389/fonc.2018.00351. eCollection 2018. Review.

29.

B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.

Li L, Zhang J, Chen J, Xu-Monette ZY, Miao Y, Xiao M, Young KH, Wang S, Medeiros LJ, Wang M, Ford RJ, Pham LV.

Blood. 2018 Oct 25;132(17):1805-1817. doi: 10.1182/blood-2018-03-841015. Epub 2018 Sep 12.

30.

Different prevalence and clinical outcome of Epstein-Barr virus positive diffuse large B-cell lymphoma between North American and non-Western populations.

Yin L, Xu-Monette ZY, Brock J, Li Y, Young KH.

Ann Transl Med. 2018 Jun;6(11):236. doi: 10.21037/atm.2018.05.36. No abstract available.

31.

Development and Preliminary Evaluation of a Murine Model of Chronic Radiation-Induced Proctitis.

Ashcraft KA, Miles D, Sunday ME, Choudhury KR, Young KH, Palmer GM, Patel P, Woska EC, Zhang R, Oldham M, Dewhirst MW, Koontz BF.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1194-1201. doi: 10.1016/j.ijrobp.2018.04.061. Epub 2018 May 5.

PMID:
30012529
32.

EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management.

Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM.

Am J Hematol. 2018 Jul;93(7):953-962. doi: 10.1002/ajh.25112. Review.

33.

Correction to: miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

Huang Q, Xi J, Wang L, Wang X, Ma X, Deng Q, Lu Y, Kumar M, Zhou Z, Li L, Zeng Z, Young KH, Yi Q, Zhang M, Li Y.

J Hematol Oncol. 2018 Jul 3;11(1):90. doi: 10.1186/s13045-018-0633-1.

34.

Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.

Sun RF, Yu QQ, Young KH.

Chronic Dis Transl Med. 2018 Mar 12;4(1):29-44. doi: 10.1016/j.cdtm.2018.02.001. eCollection 2018 Mar. Review.

35.

Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.

Wang X, Cao X, Sun R, Tang C, Tzankov A, Zhang J, Manyam GC, Xiao M, Miao Y, Jabbar K, Tan X, Pang Y, Visco C, Xie Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Winter JN, Piris MA, Li S, Miranda RN, Medeiros LJ, Li Y, Xu-Monette ZY, Young KH.

Neoplasia. 2018 Jun;20(6):574-593. doi: 10.1016/j.neo.2018.03.002. Epub 2018 May 4.

36.

MYD88 L265P Mutation in Lymphoid Malignancies.

Yu X, Li W, Deng Q, Li L, Hsi ED, Young KH, Zhang M, Li Y.

Cancer Res. 2018 May 15;78(10):2457-2462. doi: 10.1158/0008-5472.CAN-18-0215. Epub 2018 Apr 27. Review.

37.

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.

Huang Q, Xia J, Wang L, Wang X, Ma X, Deng Q, Lu Y, Kumar M, Zhou Z, Li L, Zeng Z, Young KH, Yi Q, Zhang M, Li Y.

J Hematol Oncol. 2018 Apr 23;11(1):58. doi: 10.1186/s13045-018-0600-x. Erratum in: J Hematol Oncol. 2018 Jul 3;11(1):90.

38.

Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.

Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, Pogue E, Ding Z, Lam L, Westin J, Davis RE, Young KH, Medeiros LJ, Ford RJ, Nomie K, Zhang L, Wang M.

Clin Cancer Res. 2018 Aug 15;24(16):3967-3980. doi: 10.1158/1078-0432.CCR-17-3004. Epub 2018 Apr 17.

39.

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma.

Li L, Xiao S, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Zhang X, Chang Y, Nan F, Yan J, Li Z, Shi M, Young KH, Zhang M.

Oncotarget. 2018 Jan 2;9(22):16213-16219. doi: 10.18632/oncotarget.23806. eCollection 2018 Mar 23.

40.

Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma.

Alatrash G, Perakis AA, Kerros C, Peters HL, Sukhumalchandra P, Zhang M, Jakher H, Zope M, Patenia R, Sergeeva A, Yi S, Young KH, Philips AV, Cernosek AM, Garber HR, Qiao N, Weng J, St John LS, Lu S, Clise-Dwyer K, Mittendorf EA, Ma Q, Molldrem JJ.

Clin Cancer Res. 2018 Jul 15;24(14):3386-3396. doi: 10.1158/1078-0432.CCR-17-2626. Epub 2018 Apr 16.

41.

miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy.

Xi J, Huang Q, Wang L, Ma X, Deng Q, Kumar M, Zhou Z, Li L, Zeng Z, Young KH, Zhang M, Li Y.

Oncogene. 2018 Jun;37(23):3151-3165. doi: 10.1038/s41388-018-0178-3. Epub 2018 Mar 15.

42.

Indolent T-lymphoblastic proliferation associated with low grade follicular dendritic cell sarcoma and Castleman disease.

Quesada AE, Young KH, Medeiros LJ, Thakral B.

Pathology. 2018 Apr;50(3):351-352. doi: 10.1016/j.pathol.2017.09.017. Epub 2018 Mar 2. No abstract available.

PMID:
29486963
43.

Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.

Chahoud J, Sui D, Erwin WD, Gulbis AM, Korbling M, Zhang M, Ahmed S, Alatrash G, Anderlini P, Ciurea SO, Oran B, Fayad LE, Bassett RL Jr, Jabbour EJ, Medeiros LJ, Macapinlac HA, Young KH, Khouri IF.

Clin Cancer Res. 2018 May 15;24(10):2304-2311. doi: 10.1158/1078-0432.CCR-17-3561. Epub 2018 Feb 23.

44.

Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.

García-Barchino MJ, Sarasquete ME, Panizo C, Morscio J, Martinez A, Alcoceba M, Fresquet V, Gonzalez-Farre B, Paiva B, Young KH, Robles EF, Roa S, Celay J, Larrayoz M, Rossi D, Gaidano G, Montes-Moreno S, Piris MA, Balanzategui A, Jimenez C, Rodriguez I, Calasanz MJ, Larrayoz MJ, Segura V, Garcia-Muñoz R, Rabasa MP, Yi S, Li J, Zhang M, Xu-Monette ZY, Puig-Moron N, Orfao A, Böttcher S, Hernandez-Rivas JM, Miguel JS, Prosper F, Tousseyn T, Sagaert X, Gonzalez M, Martinez-Climent JA.

J Pathol. 2018 May;245(1):61-73. doi: 10.1002/path.5060. Epub 2018 Mar 30.

PMID:
29464716
45.

Correction: STING expression and response to treatment with STING ligands in premalignant and malignant disease.

Baird JR, Feng Z, Xiao HD, Friedman D, Cottam B, Fox BA, Kramer G, Leidner RS, Bell RB, Young KH, Crittenden MR, Gough MJ.

PLoS One. 2018 Feb 15;13(2):e0192988. doi: 10.1371/journal.pone.0192988. eCollection 2018.

46.

Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.

Liu W, Chen J, Tamayo AT, Ruan C, Li L, Zhou S, Shen C, Young KH, Westin J, Davis RE, Hu S, Medeiros LJ, Ford RJ, Pham LV.

Oncotarget. 2017 Aug 21;9(1):346-360. doi: 10.18632/oncotarget.20378. eCollection 2018 Jan 2.

47.

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.

Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, Zhang X, Chang Y, Sun Z, Yu H, Zhang L, Wang X, Wu J, Li Z, Nan F, Tian L, Li W, Young KH.

J Hematol Oncol. 2018 Jan 31;11(1):15. doi: 10.1186/s13045-018-0559-7.

48.

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

Xu-Monette ZY, Zhang M, Li J, Young KH.

Front Immunol. 2017 Dec 4;8:1597. doi: 10.3389/fimmu.2017.01597. eCollection 2017. Review.

49.

Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma.

Ferrufino-Schmidt MC, Medeiros LJ, Liu H, Clemens MW, Hunt KK, Laurent C, Lofts J, Amin MB, Ming Chai S, Morine A, Di Napoli A, Dogan A, Parkash V, Bhagat G, Tritz D, Quesada AE, Pina-Oviedo S, Hu Q, Garcia-Gomez FJ, Jose Borrero J, Horna P, Thakral B, Narbaitz M, Hughes RC 3rd, Yang LJ, Fromm JR, Wu D, Zhang D, Sohani AR, Hunt J, Vadlamani IU, Morgan EA, Ferry JA, Szigeti R, C Tardio J, Granados R, Dertinger S, Offner FA, Pircher A, Hosry J, Young KH, Miranda RN.

Am J Surg Pathol. 2018 Mar;42(3):293-305. doi: 10.1097/PAS.0000000000000985.

PMID:
29194092
50.

Diffuse large B-cell lymphoma.

Li S, Young KH, Medeiros LJ.

Pathology. 2018 Jan;50(1):74-87. doi: 10.1016/j.pathol.2017.09.006. Epub 2017 Nov 20. Review.

PMID:
29167021

Supplemental Content

Loading ...
Support Center